Literature DB >> 12969105

Neither vasopressin nor amiodarone improve CPR outcome in an animal model of hypothermic cardiac arrest.

B Schwarz1, P Mair, H Wagner-Berger, K H Stadlbauer, S Girg, V Wenzel, K H Lindner.   

Abstract

BACKGROUND: Aim of this experimental animal study was to investigate the influence of vasopressin and amiodarone on cardiopulmonary resuscitation (CPR) outcome in a pig model of hypothermic cardiac arrest.
METHODS: After surface cooling to a core temperature of 26 degrees C, ventricular fibrillation was induced in 14 12-16-week-old domestic pigs. After 15 min of untreated cardiac arrest, a manual closed chest CPR was started and pigs were randomly assigned to two treatment groups: Group 1 pigs (n = 7) received vasopressin 0.4 U kg-1 as initial drug therapy, followed by a combination vasopressin (0.4 U kg-1) and amiodarone (4 mg kg-1) as subsequent drug therapy. Subsequent drug therapy was administered in animals without permanent restoration of spontaneous circulation after a first series of electrical countershocks 10 min after drug administration. Group 2 pigs (n = 7) received saline placebo as initial drug therapy and saline placebo and amiodarone (4 mg kg-1) as subsequent drug therapy.
RESULTS: Vasopressin significantly increased coronary perfusion pressure and defibrillation success (successful defibrillation in five of seven Group 1 vs. none of seven Group 2 pigs, P = 0.02). Due to refibrillation within 30-150 s, the 60-min survival rate was not improved by vasopressin. Subsequent drug therapy with amiodarone had no further effect on defibrillation success or the refibrillation rate.
CONCLUSIONS: Data from this experimental animal model suggest that vasopressin and amiodarone may not be beneficial for treatment of ventricular fibrillation associated with severe hypothermia when concomitant measures at core rewarming are not applied.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969105     DOI: 10.1034/j.1399-6576.2003.00214.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

Review 1.  [Avalanche emergencies. Review of the current situation].

Authors:  P Paal; W Beikircher; H Brugger
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

2.  An Effective and Reproducible Model of Ventricular Fibrillation in Crossbred Yorkshire Swine (Sus scrofa) for Use in Physiologic Research.

Authors:  James M Burgert; Arthur D Johnson; Jose C Garcia-Blanco; W John Craig; Joseph C O'Sullivan
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

3.  [A new method for establishing a ventricular fibrillation model by TCEI in Tibetan miniature pig].

Authors:  Guodong Liang; Rugang Zheng; Hongjian Jian; Minhai Zhang; Huiqiong Yuan; Jiemin Hong; Gang Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-11-30

Review 4.  Drug administration in animal studies of cardiac arrest does not reflect human clinical experience.

Authors:  Joshua C Reynolds; Jon C Rittenberger; James J Menegazzi
Journal:  Resuscitation       Date:  2007-03-13       Impact factor: 5.262

5.  Benefits of standardizing the treatment of arrhythmias in the sheep (Ovis aries) model of chronic heart failure after myocardial infarction.

Authors:  Adrienne Dardenne; Carlos Fernandez; Alyssa Wagner; Krzysztof Milewski; Diane R Ordanes; Patricia A Mount; Yanping Cheng; Geng-Hua Yi; Gerard B Conditt; Armando Tellez; Greg L Kaluza; Juan F Granada; William P Feeney
Journal:  J Am Assoc Lab Anim Sci       Date:  2013       Impact factor: 1.232

6.  Main complications of mild induced hypothermia after cardiac arrest: a review article.

Authors:  Hassan Soleimanpour; Farzad Rahmani; Samad Ej Golzari; Saeid Safari
Journal:  J Cardiovasc Thorac Res       Date:  2014-03-21

7.  Effects of Intraosseous Tibial vs. Intravenous Vasopressin in a Hypovolemic Cardiac Arrest Model.

Authors:  Justin Fulkerson; Robert Lowe; Tristan Anderson; Heather Moore; William Craig; Don Johnson
Journal:  West J Emerg Med       Date:  2016-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.